Sign in
Taking people in United StatesPhase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Key facts

Who runs it
UMC Utrecht
Where
Ann Arbor, Augusta, Chicago, Columbus, Jacksonville, New Orleans, New York, Pittsburgh, Portland, Providence, and Winston-Salem, United StatesSee the 11 sitesAlso in 28 other countries, 397 sites
Status
Recruiting
Phase
Phase 3
People taking part
20,000 people, planned
Started
11 Apr 2016
Expected to end
Feb 2029
Type of study
Interventional, 19 groups
Treatments tested
  • Ceftriaxone + Macrolide
  • Moxifloxacin or Levofloxacin
  • Piperacillin-tazobactam + Macrolide
  • Ceftaroline + Macrolide
  • Amoxicillin-clavulanate + Macrolide
  • Standard course macrolide
  • Extended course macrolide
  • No systemic corticosteroid
  • Fixed-duration Hydrocortisone
  • Shock-dependent hydrocortisone
  • Fixed-duration higher dose Hydrocortisone
  • No antiviral agent for influenza
  • Five-days oseltamivir
  • Ten-days oseltamivir
  • No antiviral agent for COVID-19
  • Lopinavir / Ritonavir
  • Hydroxychloroquine
  • Hydroxychloroquine + lopinavir/ritonavir
  • Ivermectin
  • No immune modulation for COVID-19
  • Interferon beta-1a
  • Anakinra
  • Tocilizumab
  • Sarilumab
  • Local standard venous thromboprophylaxis
  • Therapeutic dose anticoagulation
  • Conventional low dose thromboprophylaxis
  • Intermediate dose thromboprophylaxis
  • Continuation of therapeutic dose anticoagulation
  • No immunoglobulin
  • Convalescent plasma
  • Delayed administration of convalescent plasma
  • No vitamin C
  • Vitamin C
  • No antiplatelet
  • Aspirin
  • P2Y12 inhibitor
  • No simvastatin
  • Simvastatin
  • Eritoran
  • Apremilast
  • Clinician-preferred mechanical ventilation strategy
  • Protocolised mechanical ventilation strategy
  • No renin-angiotensin system inhibitor
  • Angiotensin converting enzyme inhibitor
  • Angiotensin Receptor Blockers
  • ARB + DMX-200
  • No cysteamine
  • Cysteamine
  • Fixed-duration dexamethasone
  • Baloxavir Marboxil
  • Five-days oseltamivir + baloxavir marboxil
  • Ten-days oseltamivir + baloxavir marboxil
  • No endothelial modulator
  • Imatinib
  • No Immune Modulator for Influenza
  • Baricitinib
  • Nirmatrelvir/ritonavir
  • Remdesivir
  • Nirmatrelvir/ritonavir + remdesivir
Record updated
4 November 2026

Who can take part

Age
28 days and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Other criteria

  • The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when:
  • All Platform inclusion criteria are met
  • None of the Platform exclusion criteria are met
  • Domain-specific eligibility criteria are met
  • The patient is eligible for at least two interventions within a domain; As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform; --; PLATFORM INCLUSION CRITERIA:
  • Hospitalised patient
  • Acute respiratory tract infection
  • Aged 28 days or older; PLATFORM EXCLUSION CRITERIA:
  • Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  • Patient is expected to be discharged from hospital within the next 24 hours
  • Previous participation in this REMAP within the last 90 days; DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:; Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org)

Where in United States

Also in 28 other countries, 397 sites

  • University of MichiganAnn Arbor, United StatesContact: Robert Hyzy, MDTaking people
  • Augusta UniversityAugusta, United StatesContact: Jose Vazquez, MDNot yet recruiting
  • University of Illinois HealthChicago, United StatesContact: Jeffrey Jacobson, MDTaking people
  • The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Matthew Exline, MDTaking people
  • University of FloridaJacksonville, United StatesContact: Hadi Hatoum, MDTaking people
  • Tulane Medical CenterNew Orleans, United StatesContact: Joshua Denson, MDNot yet recruiting
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Stephen Pastores, MDTaking people
  • University of Pittsburgh Medical CentrePittsburgh, United StatesContact: Stephanie MongomeryTaking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Akram Khankhana, MDTaking people
  • Brown University/Rhode Island HospitalProvidence, United StatesContact: Mitchell Levy, MDNot yet recruiting
  • Wake Forest Baptist HealthWinston-Salem, United StatesContact: Ashish Khanna, MDNot yet recruiting

About the trial

What the trial wants to find out

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

Read full original descriptionShow less

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

The 19 groups in the trial

  • Antibiotic DomainOther group

    Patients with community-acquired pneumonia and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment.

    Treatment: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, and Amoxicillin-clavulanate + Macrolide

  • Macrolide Duration DomainOther group

    Patients with community-acquired pneumonia who have been allocated to receive a beta-lactam + macrolide intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy

    Treatment: Standard course macrolide and Extended course macrolide

  • Corticosteroid DomainOther group

    Patients with severe lower-respiratory tract infection will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Note: the fixed-course hydrocortisone has been closed to recruitment

    Treatment: No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, and Fixed-duration dexamethasone

  • Influenza Antiviral DomainOther group

    Patients with microbiological testing confirmed influenza infection will be randomised to one of six interventions.

    Treatment: No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, and Ten-days oseltamivir + baloxavir marboxil

  • COVID-19 Antiviral DomainOther group

    Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed.

    Treatment: No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, and Ivermectin

  • COVID-19 Immune Modulation DomainOther group

    Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed.

    Treatment: No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, and Sarilumab

  • Anticoagulation DomainOther group

    Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.

    Treatment: Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, and Continuation of therapeutic dose anticoagulation

  • Immunoglobulin DomainOther group

    Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients.

    Treatment: No immunoglobulin, Convalescent plasma, and Delayed administration of convalescent plasma

  • Vitamin C DomainOther group

    Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed.

    Treatment: No vitamin C and Vitamin C

  • Simvastatin DomainOther group

    Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed.

    Treatment: No simvastatin and Simvastatin

  • Antiplatelet DomainOther group

    Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed.

    Treatment: No antiplatelet, Aspirin, and P2Y12 inhibitor

  • Mechanical Ventilation DomainOther group

    Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy

    Treatment: Clinician-preferred mechanical ventilation strategy and Protocolised mechanical ventilation strategy

  • COVID-19 Immune Modulation (2) DomainOther group

    Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed.

    Treatment: No immune modulation for COVID-19, Eritoran, and Apremilast

  • ACE2 RAS DomainOther group

    Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed.

    Treatment: No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, and ARB + DMX-200

  • Cysteamine DomainOther group

    Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed.

    Treatment: No cysteamine and Cysteamine

  • Endothelial DomainOther group

    Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.

    Treatment: No endothelial modulator and Imatinib

  • Influenza Immune ModulationOther group

    Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.

    Treatment: No Immune Modulator for Influenza, Tocilizumab, and Baricitinib

  • COVID-19 Antiviral (II) DomainOther group

    Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.

    Treatment: No antiviral agent for COVID-19, Nirmatrelvir/ritonavir, Remdesivir, and Nirmatrelvir/ritonavir + remdesivir

  • Tropical Antibiotic DomainOther group

    Patients with community-acquired pneumonia in regions at locations where or when empiric cover for melioidosis is appropriate, and requiring empiric antibiotic therapy including cover for melioidosis, will be randomised one of two antibiotic interventions

    Treatment: Amoxicillin-clavulanate + Ceftazidime + Macrolide and Meropenem + Macrolide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Publications
Record updated
4 November 2026